Codi Gharagouzloo, Ph.D., is the scientific founder and CEO of Imaginostics, a health tech startup specializing in the development of groundbreaking vascular imaging biomarkers. Based in Lake Nona Medical City, Orlando, FL, Imaginostics is at the forefront of revolutionizing precision medicine. Dr. Gharagouzloo's leadership and innovation have been central to the development of the Quantitative Ultra-short Time-to-echo Contrast-Enhanced (QUTE-CE) MRI technology, which is reshaping diagnostic approaches for longevity and in neurology, cardiology, and oncology.Dr. Gharagouzloo, an expert in MRI physics and nanoparticle contrast-enhanced imaging, earned his Ph.D. in Bioengineering from Northeastern University. His academic journey included a transformative two-year T-32 postdoctoral fellowship at the Gordon Center for Medical Imaging, Massachusetts General Hospital, and Harvard Medical School. He obtained his Master of Science in Biophotonics from the Ecole Normale Supérieure de Paris-Saclay, France, specializing in nonlinear optical microscopy. His undergraduate education resulted in dual Bachelor of Science degrees in Physics and Mechanical & Nuclear Engineering from Kansas State University, complemented by a tenure as a National Science Foundation research fellow in particle physics at the Eidgenössische Technische Hochschule in Zürich, Switzerland.In 2018, Dr. Gharagouzloo founded Imaginostics to translate his groundbreaking quantum physics based medical imaging invention from the bench to bedside. The company's focus is on addressing complex diseases through innovative, gadolinium-free, and renal-safe imaging solutions that offer unparalleled insight into vascular structures, including those around metallic vascular implants. The QUTE-CE MRI technology offers tenfold enhancement of soft tissue visualization compared to traditional gadolinium-based methods and offers the first suite of precision medicine imaging biomarkers for vascular assessment.Dr. Gharagouzloo's work is driven by a passion for creating the next generation of precision medicine diagnostic tools to understand the brain, and to transform personalized healthcare, accelerate drug development, and fight aging. He leads Imaginostics with a vision to provide early, precise, and less invasive diagnostic solutions, facilitate effective patient stratification in clinical trials, and map the real-time pharmacokinetics of drugs.